Moyamoya Disease Drug Market Size

Moyamoya Disease Market size is expected to cross USD 2.8 Billion by the end of 2036, growing at a CAGR of 5.5% during the forecast period, i.e., 2024-2036. In the year 2023, the industry size of moyamoya disease was over USD 1.4 Billion. The rising incidence of moyamoya disease in females, particularly in those under 20, is responsible for the market's expansion. With a female-to-male ratio of 1.8, the prevalence for men and women was 11.5 and 20.6 correspondingly across the globe.

In addition, it is mentioned that the main driver of the moyamoya disease market is rising public awareness. People are becoming more knowledgeable about the various kinds of neurological illnesses these days. Through conferences and seminars, the government and other organizations have been educating the public about diseases and hygiene. People are growing more attentive of their health and more aware. Consequently, rising awareness has propelled the market's expansion. Both fresh and seasoned marketers are helping to manage this situation. For example, the FDA approved Silk Road Medical, Inc.'s next-generation ENROUTE Trans carotid Neuroprotection System (NPS) on April 13, 2016. The NPS is intended and specifically built for the revascularization of the carotid arteries.